Trials / Completed
CompletedNCT02307643
Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients
An Exploratory Study of MT-1303 in Subjects With Systemic Lupus Erythematosus (a Multicenter, Open-label Study)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety/tolerability and to explore the efficacy of MT-1303 in subjects with systemic lupus erythematosus
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MT-1303 Low dose | |
| DRUG | MT-1303 High dose |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2017-05-01
- Completion
- 2017-05-01
- First posted
- 2014-12-04
- Last updated
- 2017-06-14
Locations
14 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02307643. Inclusion in this directory is not an endorsement.